Pfizer’s Talzenna Fails to Win FDA Panel Approval for Expanded Use in Prostate Cancer Treatment Amid Growing Focus on AI-Driven Clinical Trial Inclusion.
A US Food and Drug Administration (FDA) advisory panel has rejected Pfizer’s bid to expand the use of its drug Talzenna (talazoparib) to treat metastatic prostate cancer. The panel’s decision was based on the results of a clinical trial that failed to show a significant improvement in overall survival for patients taking Talzenna compared to those receiving standard therapy.
Talzenna is a poly (ADP-ribose) polymerase (PARP) inhibitor that is currently approved for the treatment of breast cancer in patients with a specific genetic mutation. Pfizer had hoped to expand the label to include prostate cancer, but the FDA panel’s decision suggests that the company will need to provide additional data to support this use.
The rejection comes as the use of artificial intelligence (AI) in clinical trials is gaining attention, particularly in the area of diversity. Clinical trials have traditionally been criticized for lacking diversity, with many studies enrolling predominantly white patients. AI has the potential to help improve diversity in clinical trials by identifying and recruiting patients from underrepresented groups.
In the case of the Talzenna trial, the lack of diversity in the patient population may have contributed to the panel’s decision. The trial enrolled mostly white patients, which may not accurately reflect the broader population of patients with prostate cancer. The use of AI could help to identify and recruit a more diverse group of patients for future trials, which could provide more accurate and representative results.
Despite the setback, Pfizer is likely to continue exploring the use of Talzenna in prostate cancer, potentially using AI to improve the diversity of future clinical trials. The company may also consider conducting additional studies to address the concerns raised by the FDA panel. The use of AI in clinical trials has the potential to revolutionize the way that new treatments are developed and tested, and it will be interesting to see how this technology is used in the development of future cancer therapies.
The FDA panel’s decision highlights the need for more diverse and representative clinical trials, and the potential role that AI can play in achieving this goal. As the use of AI in clinical trials continues to evolve, it is likely that we will see more diverse and representative patient populations, which could lead to more effective and targeted treatments for a range of diseases, including cancer.
Piramal Pharma Limited Boosts Biologics Production Capabilities to Boost Drug Development Efficiency – geneonline.com
Piramal Pharma Limited, a leading global pharmaceutical company, has announced its strategic investment in advanced biologics manufacturing to enhance drug development efficiency. This move is expected to strengthen the company’s capabilities in the biopharmaceutical sector and enable it to better serve its clients and partners.
The investment will focus on developing and implementing cutting-edge technologies and processes in biologics manufacturing, including cell line development, fermentation, and purification. By leveraging these advanced technologies, Piramal Pharma aims to improve the efficiency, productivity, and quality of its biologics manufacturing operations.
The company’s decision to invest in biologics manufacturing is driven by the growing demand for biologic therapies, which are increasingly being used to treat a range of diseases, including cancer, autoimmune disorders, and rare genetic disorders. Biologics are complex molecules that require specialized manufacturing processes, and Piramal Pharma’s investment is expected to enable it to meet the growing demand for these therapies.
The advanced biologics manufacturing capabilities will be integrated into Piramal Pharma’s existing facilities, which will enable the company to offer a seamless and integrated service to its clients, from early-stage development to commercial manufacturing. The company’s expertise in biologics manufacturing will also enable it to support the development of novel therapies, including gene therapies and cell therapies.
Piramal Pharma’s investment in biologics manufacturing is also expected to enhance its competitiveness in the global pharmaceutical market. The company’s advanced manufacturing capabilities will enable it to differentiate itself from its competitors and establish itself as a leading player in the biopharmaceutical sector.
The investment in biologics manufacturing is part of Piramal Pharma’s broader strategy to enhance its capabilities in drug development and manufacturing. The company has also been investing in other areas, including small molecule manufacturing, pharmaceutical services, and pharmaceutical research and development.
Overall, Piramal Pharma’s investment in advanced biologics manufacturing is expected to have a positive impact on the company’s growth and competitiveness in the global pharmaceutical market. The company’s enhanced capabilities in biologics manufacturing will enable it to better serve its clients and partners, and support the development of novel therapies that can improve human health. With its strong expertise in biologics manufacturing, Piramal Pharma is well-positioned to capitalize on the growing demand for biologic therapies and establish itself as a leading player in the biopharmaceutical sector.
Aurobindo Pharma Foundation provides students with specialised training driven by industry expertise.
On Thursday, a ceremony was held in Pydibhimavaram, Srikakulam district, to award certificates to 28 students who successfully completed a course on “Pharmaceutical Quality Control Analytical Techniques”. The certificates were handed over by K. Kamalakar Reddy, Head and Senior General Manager of the Aurobindo Pharma Foundation, along with management consultant S. Dayanannda. The course is designed to provide practical knowledge and skills to students in the pharmaceutical sector, particularly in the area of quality control and analytical techniques.
According to Mr. Kamalakar Reddy, the establishment of bulk drug industries in India and abroad has created a promising future for students who pursue pharmaceutical and related skill development courses. The Aurobindo Pharma Foundation is supporting M.Sc. graduates to undertake this course, with the aim of providing them with hands-on experience and understanding of the changes taking place in the manufacturing of bulk drugs.
The skill development program is an initiative of the Aurobindo Pharma Foundation, which is committed to promoting education and skill development in the pharmaceutical sector. The program is designed to equip students with the necessary skills and knowledge to pursue a career in the industry. The faculty members and program in-charge, Manohar Reddy, were also present at the ceremony to congratulate the students on their achievement.
The awarding of certificates to the students marks a significant milestone in their academic and professional journey. The course has provided them with a comprehensive understanding of pharmaceutical quality control and analytical techniques, which will enable them to make a valuable contribution to the industry. The Aurobindo Pharma Foundation’s initiative is a step in the right direction, as it addresses the need for skilled professionals in the pharmaceutical sector and provides opportunities for students to acquire practical knowledge and skills.
Overall, the ceremony was a celebration of the students’ achievement and a testament to the Aurobindo Pharma Foundation’s commitment to promoting education and skill development in the pharmaceutical sector. With the growing demand for skilled professionals in the industry, initiatives like this are essential to bridging the gap between academia and industry, and providing students with the necessary skills and knowledge to succeed in their chosen careers.
Larsen & Toubro to construct hospitals valued at Rs 24 billion for Apollo, as reported by Construction World.
Larsen & Toubro (L&T), a leading Indian multinational conglomerate, has bagged a significant contract from Apollo Hospitals to build multiple hospitals across the country. The total value of the contract is estimated to be around Rs 24 billion (approximately $330 million USD). This project aims to enhance the healthcare infrastructure in India and provide world-class medical facilities to patients.
As part of this contract, L&T will be responsible for designing, building, and delivering several hospitals, with a total capacity of over 4,000 beds. The hospitals will be equipped with state-of-the-art medical equipment and will offer a wide range of specialties, including cardiology, neurology, oncology, and more. The project is expected to be completed within the next 3-4 years, with the first phase set to be operational within the next 2 years.
This contract win is a significant milestone for L&T, as it showcases the company’s expertise in the healthcare sector. L&T has a proven track record of delivering large-scale infrastructure projects, including hospitals, and this contract demonstrates the company’s ability to execute complex projects. The project will also generate employment opportunities for thousands of skilled and unskilled workers, contributing to the country’s economic growth.
Apollo Hospitals, one of the largest hospital chains in India, has partnered with L&T to expand its healthcare services across the country. The company aims to provide accessible and affordable healthcare to a larger population, and this project is a step towards achieving that goal. The new hospitals will be designed to provide a patient-centric experience, with a focus on comfort, convenience, and care.
The construction of these hospitals will also contribute to the Indian government’s initiatives to improve healthcare infrastructure in the country. The government has been actively promoting investments in the healthcare sector, and this project is a testament to the country’s growing healthcare market. With the increasing demand for quality healthcare services, India is expected to become a hub for medical tourism, and this project will play a significant role in catering to that demand.
In conclusion, the contract between L&T and Apollo Hospitals is a significant development in the Indian healthcare sector. The project will not only enhance the country’s healthcare infrastructure but also generate employment opportunities and contribute to the country’s economic growth. With L&T’s expertise in construction and Apollo Hospitals’ experience in healthcare, this project is expected to deliver world-class medical facilities to patients across the country.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.